Optical Frequency Domain Imaging (OFDI) Assessed Strut Coverage of New Terumo DES

Exclusion Criteria

• •\- Patient has known allergy to sirolimus, cobalt, chromium, nickel, or contrast agent (that cannot be adequately premedicated)
• •Patient is not a suitable candidate for use of Dual Anti-Platelet Therapy (DAPT) because of active or recent bleedings or for use of vitamin K antagonist, like warfarin, dabigatran, rivaroxaban or acenocoumarol;
• •Patient is presenting with ST-segment elevated MI (STEMI) at baseline procedure
• •Patient has Killip-class \> 1 at admission
• •Patient is in cardiogenic shock
• •Patient is a female of childbearing potential
• •Patient has life expectancy of less then 1 year
• •Patient is expected to undergo major surgery within 3 months
• •Patient has Left Main disease ≥ 50%
• •Target lesion at bifurcation requiring 2 stents technique
• •Target lesions are severely calcified
• •Target lesion is located within 3 mm of aorta-ostium
• •Patient has renal failure defined as estimated Glomerular Filtration Rate (eGFR) \<50 mL/min/1.73m²
• •Target lesions require preparation other than balloon pre-dilatation
• •Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; Note: Trials requiring extended follow-up for products that were investigational, but have become commercially available since then, are not considered investigational trials
• •In the Investigator's opinion patient has (a) co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study
• •Patient is under judicial protection (France only)